Citi reinstates Johnson Matthey stock with neutral rating

Citi reinstated coverage of Johnson Matthey (JMAT:LON) with a Neutral rating and a £18.00 price target following the sale of its Catalyst Technologies business. The sale signals a strategic shift towards boosting cash generation, with the company targeting over £250 million in annual free cash flow by fiscal year 2028 and plans to return over £200 million per year to investors. Citi's analysis suggests the transaction highlights the potential undervalued nature of chemical assets and estimates the present value of shareholder cash returns at nearly £17 per share.

Analysis

Citi analysts have reinstated coverage on Johnson Matthey PLC (LSE:JMAT) with a Neutral rating and an £18.00 price target, following the company's sale of its Catalyst Technologies business. This divestiture signals a significant strategic pivot for Johnson Matthey, with management now prioritizing enhanced cash generation. The company has set ambitious targets, aiming to generate over £250 million in free cash flow annually from fiscal year 2028 and to return more than £200 million per year to investors. Citi views this strategic refocus as congruent with Johnson Matthey's core industrial capabilities. Furthermore, the analysts suggest that the sale of Catalyst Technologies underscores a potentially high intrinsic value in specific chemical assets, a value that may not be fully appreciated by current equity market valuations, potentially attracting strategic buyer interest in the sector. Citi's valuation analysis estimates the present value of future shareholder cash returns at nearly £17 per share, with an implied discounted payback period for the stock of approximately 21 years. The reinstated Neutral rating reflects a cautious stance as Johnson Matthey navigates this transitional period.

Key Decisions for Investors

• Given the Neutral rating and the ongoing strategic transition, investors might consider holding existing positions while closely monitoring the company's progress towards its stated free cash flow and shareholder return targets.
• The valuation metrics, including a present value of shareholder returns near £17 and an £18 price target, suggest limited immediate upside, warranting a patient approach until further clarity on the execution of the new strategy emerges.
• Investors should observe any developments related to potential M&A interest in the chemical assets sector, as highlighted by Citi, which could serve as a future catalyst for the stock.